Interpace Biosciences (IDXG) Stock Price, News & Analysis

Company Overview

Interpace Biosciences, Inc. is a molecular diagnostics company focused on improving the diagnosis and management of cancer and other complex diseases. The company develops and commercializes molecular tests that help physicians evaluate disease risk, guide treatment decisions and reduce uncertainty associated with conventional diagnostic procedures.

Its portfolio has included tests for thyroid, pancreatic and gastroesophageal conditions. ThyGeNEXT and ThyraMIR are designed to help evaluate indeterminate thyroid nodules, while PancraGEN supports risk assessment for pancreatic cysts. The company has also offered BarreGEN, a molecular test intended to assist in assessing the progression risk of Barrett’s esophagus. Interpace’s services combine molecular analysis with pathology and clinical interpretation.

The company was formed following the separation of the diagnostics business from PDI, Inc., and operated for a period as Interpace Diagnostics Group before adopting the Interpace Biosciences name. Its products have been marketed primarily to health care providers and laboratories in the United States. Interpace has also pursued collaborations and commercial relationships intended to expand the use of molecular diagnostics in oncology and related specialties.

Key Stats

• Today's Range: $6.20 to $6.25
• 50-Day Range: $4.95 to $8.50
• 52-Week Range: $4.95 to $7.45
• Volume: 1,802 shs
• Average Volume: 1,678 shs
• Market Capitalization: $34.35 million
• P/E Ratio: 15.50
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Interpace Biosciences Stock Analysis - MarketRank™

Interpace Biosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Interpace Biosciences.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Interpace Biosciences is 15.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.43.

Price to Earnings Ratio vs. Sector

The P/E ratio of Interpace Biosciences is 15.50, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.53.

Price to Book Value per Share Ratio

Interpace Biosciences has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Interpace Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Interpace Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Interpace Biosciences has recently increased by 550.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Interpace Biosciences does not currently pay a dividend.

Dividend Growth

Interpace Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.43

News Sentiment

Interpace Biosciences has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Interpace Biosciences this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Interpace Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.93% of the stock of Interpace Biosciences is held by insiders.

Percentage Held by Institutions

5.73% of the stock of Interpace Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: OTCMKTS:IDXG
• CIK: 1054102
• Web: www.interpace.com
• Phone: 855-776-6419
• Fax: 862-207-7820
• Employees: 102
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.40
• Trailing P/E Ratio: 15.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $24.58 million
• Net Margins: 67.64%
• Pretax Margin: 11.06%
• Return on Equity: 145.40%
• Return on Assets: 87.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.22
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $38.73 million
• Price / Sales: 0.89
• Cash Flow: $26.96 per share
• Price / Cash Flow: 0.23
• Book Value: $25.25 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 5,540,000
• Free Float: 5,490,000
• Market Cap: $34.35 million
• Optionable: Not Optionable
• Beta: 0.67